Bimzelx Purple Book BLA 761151

BLA number
761151
Proprietary names
Bimzelx
Proper names
bimekizumab-bkzx
Applicant
UCB, Inc.
Center
CDER
First observed release
2023-10-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Bimzelxbimekizumab-bkzx351(a)160MG/MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2023-10-17
002Bimzelxbimekizumab-bkzx351(a)160MG/MLInjectionSubcutaneousAutoinjectorRxLicensed2023-10-17
003Bimzelxbimekizumab-bkzx351(a)320MG/2ML (160MG/2ML)InjectionSubcutaneousPre-Filled SyringeRxLicensed2024-10-11
004Bimzelxbimekizumab-bkzx351(a)320MG/2ML (160MG/2ML)InjectionSubcutaneousAutoinjectorRxLicensed2024-10-11

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2024-11-01N003Bimzelx351(a)RxUCB, Inc.
2024-11-01N004Bimzelx351(a)RxUCB, Inc.
2023-10-01N001Bimzelx351(a)RxUCB, Inc.
2023-10-01N002Bimzelx351(a)RxUCB, Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2024-11-01003Bimzelx351(a)RxLicensed2024-10-11
2024-11-01004Bimzelx351(a)RxLicensed2024-10-11
2023-10-01001Bimzelx351(a)RxLicensed2023-10-17
2023-10-01002Bimzelx351(a)RxLicensed2023-10-17